Table 1

Characteristics of the study population by BMI category at baseline

VariableBMI categoryp Value
Normal (N=180)Overweight (N=200)Obese (N=197)
Age (years)50.7±14.952.3±13.253.2±10.10.04
Gender: male81 (51.6%)138 (69%)107 (54.6%)0.74
Age at diagnosis of PsA (years)36.8±14.135.1±11.638.2±12.40.002
Age at diagnosis of psoriasis (years)28.9±15.126.3±13.430.1±14.30.002
Smoker: current25 (16.1%)24 (12.1%)29 (15%)0.25
Smoker: past26 (16.8%)29 (14.7%)42 (21.7%)
Alcohol consumption: none63 (40.7%)82 (41.4%)84 (43.1%)0.63
Swollen joint count3.8±3.74.1±3.84.3±4.20.74
Tender joint count6.4±7.27.5±7.28.0±7.80.26
Damaged joint count12.3±13.314.1±15.512.6±13.60.63
PASI4.2±6.64.8±6.25.7±9.00.15
CRP (mg/L)17.3±29.011.8±12.215.9±14.60.90
ESR (mm/hr)21.5±22.020.1±18.819.3±16.30.75
HAQ0.87±0.760.91±0.710.96±0.640.10
Pain score4.3±2.84.7±2.54.9±2.50.72
Patient global score2.6±12.6±0.92.8±0.80.09
Use of NSAIDs104 (66.2%)146 (73%)157 (80.1%)0.003
Use of DMARDs90 (58.1%)122 (61.6%)125 (63.8%)0.28
Use of anti TNFα agents23 (14.7%)21 (10.6%)34 (17.4%)0.40
  • BMI, body mass index; CRP, C-reactive protein; DMARDs, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis; PASI, Psoriasis Area and Severity Index.